Brief: Poxel: PXL770 PK/PD And Phase 2a Studies In Nash Remain On Track For Results In Q2 And Q3

Poxel SA

25/05/2020 07:36

May 25 (Reuters) - POXEL SA  POXEL.PA :
    * ANNOUNCES PROGRAM UPDATE AND PRECLINICAL RESULTS ON PXL770
FOR
NASH COMBINATIONS AND OTHER METABOLIC DISEASES
    * PXL770 TREATMENT WAS OBSERVED TO IMPROVE CARDIO-RENAL
DISEASE
AND ADRENOLEUKODYSTROPHY (ALD) / ADRENOMYELONEUROPATHY (AMN) IN
ANIMAL MODELS
    * PLANS TO FURTHER EVALUATE ITS AMPK PLATFORM FOR CONTINUED
ADVANCEMENT AND PIPELINE EXPANSION IN CHRONIC AND RARE METABOLIC
DISEASES
    * PXL770 PK/PD AND PHASE 2A STUDIES IN NASH REMAIN ON TRACK
FOR
RESULTS IN Q2 AND Q3 OF 2020, RESPECTIVELY
    * POXEL SUCCESSFULLY RAISES €17.7 MILLION IN A CAPITAL
INCREASE

Source text for Eikon:  ID:nBw109XSLa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))